Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 3;13(3):564.
doi: 10.3390/diagnostics13030564.

Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review

Alessio Rizzo  1 , Manuela Racca  1 , Sara Dall'Armellina  2 , Roberto C Delgado Bolton  3 , Domenico Albano  4 , Francesco Dondi  4 , Francesco Bertagna  4 , Salvatore Annunziata  5 , Giorgio Treglia  6   7   8
Affiliations
Review

Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review

Alessio Rizzo et al. Diagnostics (Basel). .

Abstract

Background: Recently, several studies introduced the potential use of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals in radioiodine-refractory thyroid cancer (TC).

Methods: The authors accomplished a comprehensive literature search of original articles concerning the performance of PSMA-targeted PET/CT in TC patients. Original papers exploring this molecular imaging examination in radioiodine-refractory TC patients undergoing restaging of their disease were included.

Results: A total of 6 documents concerning the diagnostic performance of PSMA-targeted PET/CT in TC (49 patients) were included in this systematic review. The included articles reported heterogeneous values of PSMA-targeted PET/CT detection rates in TC, ranging from 25% to 100% and overall inferior to [18F]-fluorodeoxyglucose PET/CT when the two molecular imaging examinations were compared. Two studies reported the administration of [177Lu]PSMA-radioligands with theragnostic purpose in three patients.

Conclusions: The available literature data in this setting are limited and heterogeneous. The employment of PET with PSMA-targeting radiopharmaceuticals in this setting did not affect patient management. Nevertheless, prospective multicentric studies are needed to properly assess its potential role in TC patients.

Keywords: PET; PSMA; imaging; nuclear medicine; systematic review; thyroid; thyroid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Comprehensive overview of the study selection process for the systematic review.
Figure 2
Figure 2
Quality assessment according to QUADAS-2 tool. Authors classified the papers included in the systematic review as high risk or low risk of bias or applicability concerns for distinct domains listed in the ordinate axis. The abscissa axis shows the percentage of studies. The graph indicates that over 60% of the included studies are affected by a high risk of bias.
See this image and copyright information in PMC

References

    1. McLeod D.S.A., Zhang L., Durante C., Cooper D.S. Contemporary Debates in Adult Papillary Thyroid Cancer Management. Endocr. Rev. 2019;40:1481–1499. doi: 10.1210/er.2019-00085. - DOI - PubMed
    1. Enewold L., Zhu K., Ron E., Marrogi A.J., Stojadinovic A., Peoples G.E., Devesa S.S. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol. Biomark. Prev. 2009;18:784–791. doi: 10.1158/1055-9965.EPI-08-0960. - DOI - PMC - PubMed
    1. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E., Pacini F., Randolph G.W., Sawka A.M., Schlumberger M., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020. - DOI - PMC - PubMed
    1. Fugazzola L., Elisei R., Fuhrer D., Jarzab B., Leboulleux S., Newbold K., Smit J. 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur. Thyroid J. 2019;8:227–245. doi: 10.1159/000502229. - DOI - PMC - PubMed
    1. Tuttle R.M., Ahuja S., Avram A.M., Bernet V.J., Bourguet P., Daniels G.H., Dillehay G., Draganescu C., Flux G., Führer D., et al. Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461–470. doi: 10.1089/thy.2018.0597. - DOI - PubMed

LinkOut - more resources